Areas of expertise

Close up of people working together

We understand the science of value

As trusted partners, our areas of expertise stretch from demonstrating value through evidence-based health economics to helping clients maximize access in new and emerging therapies.  With more than two decades of experience supporting products in multiple therapeutic classes, we help brands anticipate and address the demands of value-based care at every stage of the product life cycle.

You have goals. We have experience to reach them.

Health economics and outcomes research

From complementing your in-house HEOR experts to conducting research and analysis on your behalf, our global HEOR capabilities are tailored to fit your needs.

Commercialize products and launch strategies

Gain insights into the payer mindset and translate evidence into powerful messages and strategic plans that distinguish your brand for successful product launch.

Innovative field solutions

Overcome barriers to patient access and optimize relationships between provider, patient hub, and payer with the pioneers in field reimbursement.

Real-world evidence

Generate robust real-world evidence across a wide spectrum of criteria with our data-driven solutions that prove product value and maximize patient access.

Global market access consulting

Whether you need insights from payers, providers, or patients, our experts create customized engagements that tap into the minds of critical stakeholders.

Health Policy Weekly

Stay on top of legislative changes, regulatory developments, and healthcare reform news that impacts pharmaceutical, biotech, and device manufacturers, as well as providers and managed care professionals.

   Our featured areas include:

 

Oncology

We’re built to help you navigate the complex decisions related to oncology product development and commercialization. We have worked with more than 250 different brands supporting clients, collaborating on over 2000 oncology projects.
Mutating cell

Cell and gene therapy

Ready to transform patient outcomes in this clinically promising yet commercially challenging new frontier in medicine? Let us help. We’ve commercialized every cell and gene therapy launched in the U.S.
Man in lab

Biosimilars

From supporting the first U.S. biosimilar to conducting landmark coding and reimbursement research, we are a trusted leader in the biosimilars market. Let us help you gain centralized access to FDA guidance on biosimilars and substitution laws for all 50 states.
Chemical structure on computer screen

Rare diseases and orphan products

Small patient populations face monumental challenges in rare disease states. Manufacturers are often left with information gaps that need to be addressed. From data, studies, education, and access, let us conquer the unmet needs for your most specialized therapies.
Different colored figure among many other figures

Helping your therapeutic innovations thrive

Xcenda has experience working with over 600 brands in over 30 countries and more than 470 clients with therapeutic expertise in over 20 therapeutic areas including:
  • Cardiovascular diseases
  • Dermatology
  • Endocrinology/metabolic
  • Gastroenterology
  • Immunology/inflammation
  • Infectious diseases
  • Neurology
  • Ophthalmology
  • Respiratory
  • Urology

Stay on top of an evolving landscape

Proactively position for value-based care

Understanding how payers evaluate products is key as the value-based landscape evolves. Gain insights into a wide array of methodologies and frameworks to present the most salient evidence required to survive the scrutiny.

Translate new HCEI guidance for maximum opportunity

The 21st Century Cures Act has given greater clarity to FDAMA 114, allowing new possibilities for pre-approval and proactive payer communication. Develop a strategy and suite of tools that embraces the new standards to favorably position your product in the minds of key stakeholders.

Start a conversation

We’re value drivers and problem solvers. Let us connect you with experts who understand your world and what success demands.
abstract waves